期刊
FUTURE ONCOLOGY
卷 10, 期 16, 页码 2659-2674出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon.14.201
关键词
CAF; driver mutations; EMT; HIF; hypoxia; LIMD1; NSCLC; PHD; tumor microenvironment; VHL
类别
资金
- Cancer Research UK (CRUK) [12733]
- Biotechnology and Biological Sciences Research Council (BBSRC) [BB/M000206/1]
- Biotechnology and Biological Sciences Research Council [BB/M000206/1, BB/L027755/1] Funding Source: researchfish
- Cancer Research UK [12733] Funding Source: researchfish
- Medical Research Council [1365502] Funding Source: researchfish
- BBSRC [BB/L027755/1, BB/M000206/1] Funding Source: UKRI
Since the application of molecular biology in cancer biology, lung cancer research has classically focused on molecular drivers of disease. One such pathway, the hypoxic response pathway, is activated by reduced local oxygen concentrations at the tumor site. Hypoxia-driven gene and protein changes enhance epithelial-to-mesenchymal transition, remodel the extracellular matrix, drive drug resistance, support cancer stem cells and aid evasion from immune cells. However, it is not the tumor cells alone which drive this response to hypoxia, but rather their interaction with a complex milieu of supporting cells. This review will focus on recent advances in our understanding of how these cells contribute to the tumor response to hypoxia in non-small-cell lung cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据